# Kynos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kynos-therapeutics

- Industry: Biotechnology
- Headquarters: Sheffield, UK
- Website: www.kynostx.com
- Total disclosed funding: $8.8M
- Latest round: Series A (Feb 3, 2022)
- Investors on record: 3

## About

Founded in 2020 and based in Sheffield, UK, Kynos Therapeutics Ltd., aka Kynos is a biotechnology company engaged in the development of KMO inhibitors. The company is a spin-out from the University of Edinburgh and was co-founded by its CEO, Damian Mole, and Chief Scientific Officer, Scott Webster. In April 2022, Kynos Therapeutics Ltd received GBP 2.5 million in grant funding from investor Innovate UK.

Kynos develops a pipeline of KMO (kynurenine 3-monooxygenase) inhibitors that can target KMO, an enzyme that regulates inflammation, as well as the way inflammation and metabolism control the immune system. The company’s programs are focused on enhancing the medical outcomes in three key areas including critical illness or post-surgery illness, conditions driven by inflammation (ex: endometriosis), and cancers where inflammation negatively impacts the functionality of the immune system.

Kynos intends to utilize the April 2022 funding to advance its KMO inhibitor (KMOi) programs toward Phase 1 clinical trials.

## Funding rounds

- Series A, Feb 3, 2022, $8.8M — Longview Innovation, Epidarex Capital, Scottish Enterprise

## Investors

- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series A
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A
- Scottish Enterprise (https://capitalatlas.ai/funds/scottish-enterprise) — Series A